Objective Non-HIV patients with pneumocystis pneumonia (PCP) have a poor prognosis. We aimed to evaluate the prognostic factors for in-hospital mortality in terms of the clinical findings, including the results of bronchoalveolar lavage fluid (BALF)-analyses, in non-HIV PCP patients. Methods We retrospectively reviewed non-HIV PCP patients diagnosed using bronchoalveolar lavage between April 2006 and July 2012. For patients with a poor respiratory status, noninvasive positive pressure ventilation (NPPV) was used during the bronchoalveolar lavage (BAL) procedure. Data regarding demographics, laboratory findings and the prognosis were evaluated. Results A total of 29 non-HIV PCP patients were analyzed. NPPV was carried out safely and successfully in 12 patients during the BAL procedure. Twelve patients (41%) died. The multivariate logistic regression analysis identified only BALF neutrophilia to be a significant prognostic factor determining in-hospital mortality. The log-rank test showed that the patients with BALF neutrophilia (! 31%) had a significantly lower survival rate than the other patients (p=0.001). Conclusion Only BALF neutrophilia was found to be a significant predictor of survival in patients with non-HIV PCP. Our data also emphasize the significance of performing BAL in such patients, as it provides both diagnostic and prognostic information.
Introduction
Pneumocystis pneumonia (PCP), a condition caused by Pneumocystis jirovecii, has emerged as an important cause of morbidity and mortality in non-human immunodeficiency virus (HIV) patients (1) . Although PCP is commonly associated with HIV infection, the incidence of non-HIV PCP is increasing among patients with other predisposing immunodeficiency states, such as organ transplant recipients and patients with hematologic or solid tumors and chronic inflammatory diseases requiring the prolonged use of corticosteroids (2) .
Various prognostic factors for PCP, including bronchoalveolar lavage fluid (BALF) neutrophilia, have been described (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . In cases of HIV PCP, BALF neutrophilia is associated with a high mortality rate (4, (10) (11) (12) as well as an alveolar-arterial oxygen difference (AaDO2) (13) . However, among patients with non-HIV PCP, limited reports describing the cell differential counts of BALF are available (7, 12) , and previous studies did not include patients with a severe respiratory condition. In cases of PCP, BALF analyses are useful for detecting Pneumocystis jirovecii DNA using polymerase chain reaction (PCR). It has been reported that, compared with conventional staining, PCR detection of P. jirovecii DNA provides greater sensitivity for diagnosing PCP (14) .
Determining the diagnostic significance and prognostic value of BALF analyses would confirm the importance of performing BAL. Therefore, in this study, we aimed to evaluate prognostic factors for in-hospital mortality in non-HIV PCP cases with respect to clinical findings, including the results of BALF analyses.
Materials and Methods

Patients
Our hospital is a 700-bed tertiary referral center that plays a central role in treating emergency patients in the surrounding area. We retrospectively reviewed consecutive non-HIV PCP cases diagnosed using BALF analyses between April 2006 and July 2012.
The diagnosis of PCP was made based on the fulfillment of all of the following criteria: 1) the presence of symptoms such as fever, coughing and dyspnea associated with diffuse infiltrates on chest CT, 2) the detection of P. jirovecii using Grocott's stain or qualitative pneumocystis DNA using PCR of BALF and 3) an elevated plasma 1,3-β-D-glucan level to 11 pg/mL above the cutoff value. The 1,3-β-D-glucan levels were measured using the 1,3-β-D-glucan test WAKO (Wako Pure Chemical Industries, Tokyo, Japan).
Data collection
Data regarding the patients' demographic and clinical details were retrieved from the computerized record system of the hospital. For each patient, the following information was recorded: age, gender, underlying conditions, trimethoprimsulfamethoxazole (TMP-SMX) prophylaxis, immunosuppressant or corticosteroid therapy, laboratory findings and the ratio of partial pressure of arterial O2 to the fraction of inspired O2 (PaO2/FiO2) on the diagnosis of PCP, BALF analyses findings, complications during the BAL procedure and treatment for PCP, including additional therapeutic modalities. An adequate dose of TMP-SMX was set to 15 mg/kg/ day based on the TMP component. Dosage adjustment was performed in patients with renal insufficiency in accordance with the Sanford Guide to Antimicrobial Therapy, 2012 (15) . A dose of TMP-SMX smaller than that described above was defined as an inadequate dose. Co-pathogens were examined using BALF and blood cultures, and cytomegalovirus (CMV) infection was diagnosed using a CMV antigenemia assay with a kit for CMV antigenemia testing (CMV Antigen Mitsubishi Kit, Mitsubishi Chemical Medience Corp., Tokyo, Japan). CMV antigenemia in which more than 10 positive cells/slide were detected was defined as CMV infection based on a previous report (16) . The clinical outcomes and in-hospital mortality were assessed.
BAL procedure
The BAL procedure was performed under oxygen using a nasal cannula or mask. Three doses of 50 mL or five doses of 30 mL of sterile normal saline were instilled in patients with new pulmonary involvement on chest CT and immediately aspirated through the bronchoscope. Noninvasive positive pressure ventilation (NPPV) was used in patients with a poor respiratory status in order to prevent respiratory deterioration during the procedure.
Statistics
Continuous variables are expressed as the mean ± standard deviation, unless stated otherwise. A univariate logistic regression analysis was used to identify significant variables predicting the survival status. Variables selected in the univariate analysis were evaluated using a multivariate logistic regression model. A p value of <0.05 was deemed to be statistically significant. The prognostic value of significant variables was evaluated using the area under a receiver operating characteristic (ROC) curve. Survival was expressed according to the Kaplan-Meier method, and differences were assessed using the log-rank test. All statistical analyses were performed using the JMP 9 (SAS Institute Inc., Cary, USA) software program. This study was approved by the Institutional Review Board of Kobe City Medical Center General Hospital.
Results
Patient characteristics on admission
The characteristics of the patients with PCP are summarized in Table 1 . A total of 29 non-HIV PCP patients were analyzed. The primary etiology of disease included renal transplantation (34%), rheumatoid arthritis (RA) (24%) and hematological malignancy (14%). Other etiologies included solid cancers, ulcerative colitis, microscopic polyangiitis and interstitial lung disease. Twenty-four patients received corticosteroids with/without immunosuppressants. No patients, except one with RA, received prophylaxis with TMP-SMX. The findings of bacterial cultures of the BALF were positive in 10 patients (34%), while no patients exhibited positive findings in blood. Evidence for bacterial pulmonary coinfection was established in only one case (based on significant growth in culture, the detection of bacterial phagocytosis on Gram staining and a clinical course consistent with co-infection). Positive CMV antigenemia was observed in one patient with antigenemia of 26 positive cells/slide. BALF specimens were collected at a median collection rate of 63% (range: 34% to 89%). Twelve patients (41%) underwent the BAL procedure under NPPV. No serious procedure-related complications were observed within 24 hours after the procedure.
Treatment
The treatments are summarized in Table 2 . Anti-PCP treatment with TMP-SMX was initiated in 28 patients. In 14 patients (48%), the anti-pneumocystis agents were changed due to adverse effects. Corticosteroids were used adjunctively in all patients, including 16 (55%) who received over 250 mg of methylprednisolone (mPSL) as the initial dose. Thirteen patients (45%) were managed with NPPV, and eight patients (28%) required intubation, four of whom received intubation after NPPV management. Twelve patients died (mortality rate: 41%).
Prognostic factors
According to a univariate logistic regression analysis, age, renal transplantation, PaO2/FiO2, mechanical ventilation, BALF cellularity, the levels of albumin, lactate dehydrogenase (LDH) and C-reactive protein (CRP) and the presence of BALF neutrophils and lymphocytes were found to be predictive factors for mortality ( Table 3 ). The fraction of neutrophils in the BALF was significantly higher among the deceased patients than among the survivors, whereas the fraction of lymphocytes exhibited the reverse trend. The multivariate logistic regression analysis identified only BALF neutrophilia to be a significant prognostic factor determining in-hospital mortality ( Table 4 ). The area under the ROC curve was 0.82 for BALF neutrophils. With a cutoff level of 31%, the presence of BALF neutrophils exhibited a sensitivity of 66.7% and specificity of 88.2% for predicting mortality. The log-rank test showed that the patients with BALF neutrophilia (! 31%) had a significantly lower survival rate than those without (p=0.001) (Figure) .
Discussion
In the present study, we evaluated prognostic factors for non-HIV PCP in patients with a severe respiratory condition using NPPV with BAL, as required, and found BALF neutrophilia to be a predictor of in-hospital mortality.
Among HIV patients with PCP, BALF neutrophilia is associated with a high mortality rate (4, 10-12) as well as AaDO2 (13) . Regarding cases of non-HIV PCP, Zahar et al.
reported that the detection of BALF neutrophilia in patients with mild PCP with malignancy is associated with inhospital mortality (7) . In addition, Limper et al. reported that non-HIV PCP patients exhibit significantly higher levels of neutrophils in BALF than HIV PCP patients and that increased levels of lavage neutrophils are correlated with poor oxygenation and a worse patient survival (12) . However, these studies did not include patients with severe respiratory conditions. The median PaO2/FiO2 in the above study population was over 200 mmHg, compared to the 134 mmHg observed in the present study. Our results, which demonstrated that BALF neutrophilia predicts in-hospital mortality among non-HIV PCP patients, are in line with those of studies of patients with HIV PCP and milder non-HIV PCP, suggesting that a high BALF neutrophil level is a poor prognostic factor in PCP universally.
Previous reports have indicated that neutrophils do not play a central role in the host defense against Pneumocystis infection (10) (11) (12) . Diffuse alveolar damage (DAD), which is associated with BALF neutrophilia (17) , is the most common histologic manifestation of non-HIV PCP (18) . Hence, BALF neutrophilia may be associated with DAD caused by PCP, as has been suggested in the setting of acute respiratory distress syndrome (ARDS). In patients with ARDS, overzealous neutrophil activation results in alveolar damage due to the release of cytotoxic and immune cell-activating agents (19) . However, in patients with PCP, it has been shown that neither neutrophils nor reactive oxygen species contribute to tissue damage. Using mouse models of neutrophil dysfunction, Swain et al. demonstrated that an impaired neutrophil function is not associated with tissue damage or elevated levels of Pneumocystis (20) . Therefore, while the presence of BALF neutrophilia is a valid marker of lung damage, the exact pathophysiological role of neutrophils in the development of PCP is not well understood.
It is possible that bacterial infection causes BALF neutrophilia. In the present study, co-pathogens were detected in the BALF in 10 patients (34%), although 11 (38%) of the total 29 patients received antibiotics before undergoing BAL, which may have inhibited bacterial growth. Among these patients, only one was clinically diagnosed with an active bacterial infection. Although we carefully reviewed the possibility of active bacterial infection in the other nine patients, we cannot rule out the possibility of active infection causing BALF neutrophilia in these cases. However, the fraction of BALF neutrophils did not differ between the 10 co-pathogen-positive patients and 19 co-pathogen-negative patients (27±7% vs. 25±26%, p=0.9), thus suggesting that the presence of co-pathogens is not associated with BALF neutrophilia. Furthermore, the detection of co-pathogens in the BALF was not found to be associated with mortality in this study.
According to the univariate logistic regression analysis, various factors described in previous reports, including age, renal transplantation, PaO2/FiO2, mechanical ventilation and the levels of albumin, LDH and CRP, were found to be predictive of mortality (2, 3, 4, 21) in the present study, in addition to BALF neutrophilia. However, in the multivariate analysis, BALF neutrophilia was identified to be the only prognostic factor for non-HIV PCP in patients with a severe respiratory condition.
The major limitations of this study include its retrospective design and small size as well as the heterogeneous nature of the amassed data and the use of a clinical diagnosis. While the gold standard for PCP diagnosis is the documentation of the organism in respiratory specimens, the sensitivity of this approach is not very high. Previous reports have diagnosed PCP using positive Pneumocystis PCR results (6, 9). However, PCR-based assays carry the risk of a false-positive diagnosis of PCP in patients who are colonized, but not infected, with P. jirovecii (22) . Therefore, in this study, we added the inclusion criterion of elevation of the 1,3-β-D-glucan level, which has a high sensitivity and specificity for diagnosing PCP (23) .
In summary, this study found only BALF neutrophilia to be a significant predictor of survival in patients with non-HIV PCP. In addition, performing BAL is very useful, even in the setting of NPPV, as it provides both important diagnostic and prognostic information.
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